SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee joined Irth Capitals take-private bid have renewed buyout speculation. Traders are debating whether the board will accept a deal, against the backdrop of weak sales and previous rejected offers; no transaction is confirmed.

TOSHI

TOSHI is drawing attention around a hoped-for breakout after bursts of volume and a modest rebound, with traders repeatedly watching a stubborn resistance zone and speculating about a short squeeze. Bulls are accumulating and anticipating a run, while skeptics point to repeated rejections, weak price action, and broader crypto-market risk; rumors of listings or an announcement remain unconfirmed.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer data for IMDELLTRA combined with AstraZenecas IMFINZI is drawing attention after showing a substantial survival benefit in extensive-stage small-cell lung cancer. Traders view the results as a potential growth driver for Amgens oncology pipeline, while also weighing established products such as Repatha and treating the companys AI story as a longer-term theme.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp short-term XCN price spike, with traders noting a large candle and a rapid intraday gain, is driving attention despite no specific news catalyst being identified. The community is split between buying the dip and calling the move another pump-and-dump, while some attribute the broader lift to Bitcoins rebound.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks rallied with cybersecurity peers as traders focused on an Evercore ISI survey indicating enterprise security budgets are firming and on escalating vulnerability and AI-driven cyberthreat concerns. The move drew bullish momentum commentary, while some traders questioned whether the sectors gains are justified given lofty valuations.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks partnered personalized mRNA melanoma vaccine with Moderna is drawing attention after Phase 3 results showed reduced recurrence or death risk when added to Keytruda. Traders are split between viewing the data as a meaningful oncology milestone with potential to support Keytruda and seeing it as a sell-the-news outcome that fell short of high expectations.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated ESMO subgroup analyses from Celcuitys Phase 3 VIKTORIA-1 breast-cancer study are driving discussion, with traders highlighting favorable efficacy for gedatolisib and the potential for a PIK3CA-mutant label expansion. The reaction is split between enthusiasm for the data and concern that CELC still needs to demonstrate commercial uptake and revenue; some posts also debate whether the share price reflects the clinical results.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is drawing attention after a sharp third-quarter outlook cut tied to weak demand, excess distributor inventory, and price adjustments. Traders are split between viewing the reset and debt-reduction efforts as a path to recovery and fearing that persistent pressure on sales, margins, and debt could lead to restructuring or bankruptcy.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

A broad biotech-sector pullback is the main focus, with IBB hovering near its 50-day moving average after a strong run. Traders describe the dip as a pause while others remain cautious about sector weakness, and several note that large-cap biotech is holding up better than smaller names.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvuss Phase 1 soquelitinib results in atopic dermatitis are driving discussion, with bullish traders highlighting the efficacy signal and skeptics questioning the early, limited data and follow-up. The news has prompted a mixed reaction, including complaints that shares sold off despite the positive readout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PFE NOV20 31C · still actionable

Zone: $29.82 to $30.24
Invalidation: close under $29.81
Objectives: $30.44, then $32

The math: up 1.4% to the first objective and 6.6% to the second, against 0.7% risk on the invalidation, about 9 to 1 to the second.

Think of Pfizer like a big ship that barely rocks in a storm. Friday it slipped to 29 dollars and 81 cents and buyers stepped in right there, which tells you that floor still matters. With earnings set for November 3, this November 20 call gives the story time to play out instead of expiring on the news. If the stock climbs back over its 52 week high near 30 dollars and 44 cents, the path toward 32 dollars opens up in a plain and simple way.

P.S. Friday traded 29.45 million shares, so that low at 29 dollars and 81 cents was tested in real size.

StockTwits Web

Pfizer Inc

 NOV20 31C · still actionable

Zone: $29.82 to $30.24
Invalidation: close under $29.81
Objectives: $30.44, then $32

The math: up 1.4% to the first objective and 6.6% to the second, against 0.7% risk on the invalidation, about 9 to 1 to the second.

Think of Pfizer like a big ship that barely rocks in a storm. Friday it slipped to 29 dollars and 81 cents and buyers stepped in right there, which tells you that floor still matters. With earnings set for November 3, this November 20 call gives the story time to play out instead of expiring on the news. If the stock climbs back over its 52 week high near 30 dollars and 44 cents, the path toward 32 dollars opens up in a plain and simple way.

P.S. Friday traded 29.45 million shares, so that low at 29 dollars and 81 cents was tested in real size.